Real-world data for effectiveness and safety of palopegteriparatide in patients with chronic hypoparathyroidism: the PaTH REAL study
Authors' conclusion
In a real-world setting, palopegteriparatide effectively normalizes calcium-phosphate homeostasis, reduces hypercalciuria, and substantially decreases reliance on conventional therapy, with a favorable safety profile.
Study context
- Population
- Adults with chronic hypoparathyroidism (79 females, 13 males), previously treated with recombinant human PTH (1–84) or conventional therapy79 females · 13 males
- Participants
- 92 adults
- Outcome
- Biochemical control of calcium-phosphate metabolism (baseline to follow-up)
- Follow-up
- Median 6.5 months (range 2-14) of treatment
Methodological detailsmulticentre, tertiary referral hospitals, real-world
- Multicentre
- Tertiary referral hospitals
- Real-world
Main finding
As reported in the abstract
Phosphate decreased (P < .001)
4.74 ± 0.97 to 4.02 ± 0.63 mg/dL
Ca × P product decreased (P = .017)
38.27 ± 6.92 to 36.04 ± 6.55 mg2/dL2
24-hour urinary calcium decreased (P < .001)
245.7 ± 125.5 to 164.5 ± 88.3 mg/24 h
Observational data: associations, not effects.
Further findings
Independence from calcium supplements and alfacalcidol · after a median of 30 days
- Patients achieving independence from calcium supplements and alfacalcidol
- 58%
Daily pill burden
- Daily pill burden was markedly reduced
Safety
- Adverse events were mostly mild and transient
Original publication
Real-world data for effectiveness and safety of palopegteriparatide in patients with chronic hypoparathyroidism: the PaTH REAL study. Eur J Endocrinol. Published 27 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →